Using Fexofenadine to Help Treat Parkinson's Disease
Official title: Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment
Run by Tanta University · NCT06785298 · Data updated 2026-11-12
This study is testing if adding Fexofenadine to the usual Parkinson's treatment can help improve symptoms for people with the disease.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 70 Years |
| Sex | All |
| Enrollment | 46 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | December 10, 2024 |
| Main results expected | December 10, 2026 |
| Study ends | December 20, 2026 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT06785298 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 50 and older who have been diagnosed with Parkinson's disease and are currently on dopamine replacement therapy.
✕Probably not a fit
Patients with atypical parkinsonism, significant liver or kidney dysfunction, or those with a known allergy to the study medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of Fexofenadine as an adjuvant therapy for patients with Parkinson's disease, a progressive neurological disorder. The study aims to assess the efficacy of Fexofenadine in combination with standard dopamine replacement therapy, such as Levodopa/carbidopa, in improving both motor and non-motor symptoms of the disease. Participants will be evaluated based on their response to treatment over the course of the trial, which includes phases 2 and 3 to ensure comprehensive data collection and analysis.
Why it matters
Potential benefit: If successful, this treatment could enhance the quality of life for patients with Parkinson's disease by improving their symptoms.
How similar studies have gone: While the use of Fexofenadine in this context is novel, other studies have explored various adjuvant therapies for Parkinson's disease with varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:• Age ≥ 50 years. Both male and female will be included. Patients with Parkinson's disease on dopamine replacement therapy. Modified Hoehn and Yahr stage, MHY 1-4 Exclusion Criteria:• Atypical parkinsonism or drug-induced parkinsonism Breast feeding Pregnant women and women with planned pregnancy. Patients with significant liver and kidney function abnormalities. History/presence of acute heart disease Alcohol and / or drug abusers. Patients with known allergy to the study medications Other medical conditions that can interfere with results or endanger the participant.
Where it's running
-
Tanta University
Tanta, Egypt Recruiting
Study contacts
- Study coordinator: Ihab Elsayed Hassan, Doctor
- Email: ihassan@horus.edu.eg
- Phone: 0201067831661
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.